Published in Immunology on May 01, 1992
Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev (2000) 3.69
Historical insights into cytokines. Eur J Immunol (2007) 1.71
Regulation of tumour necrosis factor (TNF) induced apoptosis by soluble TNF receptors in Helicobacter pylori infection. Gut (1999) 1.55
Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest (1998) 1.24
Time course of cytokine levels in sepsis. Intensive Care Med (1995) 1.22
Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med (1995) 1.19
A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J (1999) 1.17
Changes in immune parameters and their correction in human cases of tick-borne encephalitis. Clin Exp Immunol (2003) 1.13
Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol (2009) 1.10
Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infect Immun (1993) 0.91
Soluble tumor necrosis factor alpha receptors in sera from leprosy patients. Infect Immun (1999) 0.89
Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy? Clin Exp Immunol (1998) 0.87
Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. Eur J Clin Microbiol Infect Dis (1994) 0.87
Soluble tumour necrosis factor (TNF)-receptor levels in serum as markers of anti-viral host reactivity. Clin Exp Immunol (1999) 0.85
Release of soluble tumor necrosis factor receptors in Mediterranean spotted fever rickettsiosis. Clin Diagn Lab Immunol (1996) 0.83
Tumor necrosis factor-alpha in peripical tissue exudates of teeth with apical periodontitis. Mediators Inflamm (2007) 0.82
The role of prophylactic ibuprofen and N-acetylcysteine on the level of cytokines in periapical exudates and the post-treatment pain. Daru (2012) 0.79
Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol (2014) 0.78
Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients. Eur J Epidemiol (2000) 0.77
Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol (2011) 0.77
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A (1986) 5.60
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 4.58
Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A (1990) 3.59
Cachectin/tumour necrosis factor. Lancet (1989) 2.77
Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem (1989) 2.19
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A (1990) 2.11
Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine (1990) 1.72
Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest (1990) 1.67
Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A (1990) 1.40
Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A (1990) 1.34
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A (1990) 1.30
Is circulating tumor necrosis factor bioactive? N Engl J Med (1988) 0.90
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 10.98
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA (1999) 7.37
Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science (1987) 7.01
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med (1995) 4.57
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum (1995) 3.83
Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med (1987) 3.62
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med (1989) 3.58
Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature (1990) 3.46
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med (2001) 3.40
Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest (1979) 3.34
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest (1999) 3.19
Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 2.91
L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J Immunol (1986) 2.79
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine (1993) 2.48
Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med (1993) 2.47
Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med (1977) 2.47
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis (1990) 2.36
Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci U S A (1992) 2.34
Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett (1981) 2.27
Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J Exp Med (1991) 2.24
Is the pulmonary artery catheter misused? A European view. Crit Care Med (1998) 2.23
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem (1989) 2.07
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis (1992) 1.98
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol (1991) 1.94
Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev (2001) 1.91
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
A human inhibitor of tumor necrosis factor alpha. J Exp Med (1988) 1.85
Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology (1994) 1.81
Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum (1993) 1.79
Profiles of cytokine production in relation with susceptibility to cerebral malaria. J Immunol (1993) 1.77
Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (1979) 1.77
Organization of intensive care units in Europe: lessons from the EPIC study. Intensive Care Med (1997) 1.77
Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology (1997) 1.73
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest (1986) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Interleukin 1 is present in normal human epidermis. J Immunol (1986) 1.70
Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med (1991) 1.69
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol (1984) 1.66
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology (1992) 1.63
Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol (1989) 1.63
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol (1992) 1.62
Role of TNF and IL-1 in infections with Toxoplasma gondii. Immunology (1990) 1.61
Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem (1991) 1.57
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol (1990) 1.53
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics (1994) 1.49
Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol (1995) 1.48
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science (1989) 1.46
Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. Eur Respir J (2007) 1.45
Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol (1995) 1.45
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) (2002) 1.45
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol (1987) 1.44
Nitric oxide and cerebral malaria. Lancet (1993) 1.43
Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol (1993) 1.42
Immunopathological changes in human cerebral malaria. Clin Neuropathol (1993) 1.40
[Posterior shoulder dislocation. An often overlooked injury]. Schweiz Med Wochenschr (1990) 1.39
A simple scoring system to assess risk of hematological side effects in zidovudine recipients. AIDS (1991) 1.38
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis (1994) 1.37
Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur J Immunol (1992) 1.36
Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem (1994) 1.36
Platelets play an important role in TNF-induced microvascular endothelial cell pathology. Am J Pathol (1997) 1.35
Role of polymorphonuclear neutrophil leukocytes and their integrin CD11a (LFA-1) in the pathogenesis of severe murine malaria. Infect Immun (1994) 1.35
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Tumor necrosis factor and severe malaria. J Infect Dis (1991) 1.34
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood (1998) 1.32